Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MWN 109

Next Previous
Search
Drug Profile

MWN 109

Alternative Names: MWN-109

Latest Information Update: 31 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Minwei Biotechnology
  • Class Fatty acids; Hepatoprotectants; Obesity therapies; Peptides
  • Mechanism of Action Gastric inhibitory polypeptide receptor modulators; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-alcoholic steatohepatitis; Obesity

Most Recent Events

  • 19 Mar 2025 Preclinical trials in Non-alcoholic steatohepatitis in China (PO) (Shanghai Minwei Biotechnology pipeline, March 2025)
  • 19 Mar 2025 Preclinical trials in Non-alcoholic steatohepatitis in China (SC) (Shanghai Minwei Biotechnology pipeline, March 2025)
  • 19 Mar 2025 Shanghai Minwei Biotechnology plans to file Investigational new drug application for MWN 109 in China and USA in April 2025 (PO) (Shanghai Minwei Biotechnology website, March 2025)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top